Literature DB >> 10078630

Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients.

L de Graaf-Strukowska1, J van der Zee, W van Putten, S Senan.   

Abstract

PURPOSE: To determine the factors influencing the response to palliative radiotherapy (RT) in malignant mesothelioma of the pleura (MM). METHODS AND MATERIALS: A retrospective review was conducted of the records of all patients with mesothelioma who were referred to our institution between 1979 and 1996. A total of 227 RT series were administered to 189 patients with MM. Of these, 21 patients with chest wall nodules also received concomitant local hyperthermia.
RESULTS: The median survival was 5 months from the start of RT and only 17% of patients were alive at 1 year after treatment. Chest pain and painful chest wall metastases were the main indications for RT. A higher local response rate was seen for patients treated with a 4-Gy per fraction scheme, vs. those receiving fractions of less than 4 Gy (50% vs. 39%). Pain recurrence occurred predominantly within the previous RT field, and pain recurred after a median of 69 days (range 32-363) in the group treated using 4-Gy fractions. When compared with a matched group, patients treated with combined RT and hyperthermia had higher response rates and fewer in-field recurrences.
CONCLUSIONS: RT provides local palliation in at least 50% of patients with MM who were treated using a 4-Gy/fraction scheme to a median dose of 36 Gy. The low response rates with RT alone suggest that combined RT and local hyperthermia should be further evaluated in MM.

Entities:  

Mesh:

Year:  1999        PMID: 10078630     DOI: 10.1016/s0360-3016(98)00409-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  22 in total

1.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

2.  Current therapies for malignant pleural mesothelioma.

Authors:  Takashi Nakano
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

Review 3.  What is the role of radiotherapy in malignant pleural mesothelioma?

Authors:  Allan Price
Journal:  Oncologist       Date:  2011-02-23

Review 4.  Optimal Therapy of Advanced Stage Mesothelioma.

Authors:  Maria M J Disselhorst; Sjaak J A Burgers; Paul Baas
Journal:  Curr Treat Options Oncol       Date:  2017-08

5.  [Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline].

Authors:  Christoph Süß; Oliver Kölbl
Journal:  Strahlenther Onkol       Date:  2018-10       Impact factor: 3.621

Review 6.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

7.  Radiotherapy applications of patients with malignant mesothelioma: A single center experience.

Authors:  Muge Akmansu; Ozge Petek Erpolat; Fatih Goksel; Evrim Tunc; Can Ozturk
Journal:  Rep Pract Oncol Radiother       Date:  2012-08-09

Review 8.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

Authors:  Andrew R Haas; Daniel H Sterman
Journal:  Clin Chest Med       Date:  2013-01-17       Impact factor: 2.878

9.  A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.

Authors:  Stephanie R Rice; Yun R Li; Theresa M Busch; Michele M Kim; Sally McNulty; Andrea Dimofte; Timothy C Zhu; Keith A Cengel; Charles B Simone
Journal:  Photochem Photobiol       Date:  2018-12-28       Impact factor: 3.421

10.  The Kadota Fund International Forum 2004--clinical group consensus.

Authors:  J van der Zee; Z Vujaskovic; M Kondo; T Sugahara
Journal:  Int J Hyperthermia       Date:  2008-03       Impact factor: 3.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.